Jounce Therapeutics (JNCE) News Today → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free JNCE Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineSan Diego VC, OrbiMed make competing buyout offers for struggling Theseusbizjournals.com - November 27 at 12:12 PMJounce Media Designates Yahoo Backstage as the Open Web's Largest MFA-Free Supply Sourcetmcnet.com - September 19 at 2:48 PMKargo Is Industry’s Only Scaled 100% Premium SSP According To Jounce Mediafinance.yahoo.com - September 18 at 2:58 PMMediavine Represents the Largest Percentage of DEI-owned Websites, Per Data from Jounce Mediatmcnet.com - September 5 at 5:55 PMBoard Member at Jounce Therapeutics Exercises Options Worth $324Kbenzinga.com - May 5 at 3:51 PMBoard Member at Jounce Therapeutics Exercises Options Worth $172Kbenzinga.com - May 4 at 7:17 PMJounce Therapeutics Director Acquires 51,400 Shares After Exercising Company Stock Optionsbenzinga.com - May 4 at 2:17 PMJounce Therapeutics Board Member Acquires 1,883,269 Shares After Exercising Company Stock Optionsbenzinga.com - May 4 at 2:17 PMmarketbeat.com - May 4 at 6:03 AMJounce Therapeutics Announces Closing of Tender Offerfinance.yahoo.com - May 3 at 11:14 PMJounce Therapeutics (NASDAQ:JNCE) Now Covered by StockNews.commarketbeat.com - April 30 at 1:24 AMJNCE Jounce Therapeutics, Inc.seekingalpha.com - April 29 at 2:33 AMThe past five years for Jounce Therapeutics (NASDAQ:JNCE) investors has not been profitablefinance.yahoo.com - April 17 at 1:51 PMWhat is Wall Street's Target Price for Jounce Therapeutics Inc (JNCE) Stock Monday?benzinga.com - March 29 at 6:43 PMBuyout Offer Sends Jounce Jumping 20%msn.com - March 27 at 5:48 PMJounce Therapeutics Shares Rally on Buyout Deal >JNCEmarketwatch.com - March 27 at 12:47 PMJounce Therapeutics Agrees to Buyout, Drops Redx Deal >JNCEmarketwatch.com - March 27 at 12:47 PMJounce dumps Redx Pharma for acquisition by Concentra; to cut 84% of jobsfinance.yahoo.com - March 27 at 12:47 PMmarketbeat.com - March 27 at 8:59 AMMoore Kuehn Encourages JNCE, USX, INDT, and BHWB Investors to Contact Law Firmbenzinga.com - March 23 at 9:08 PMTang Capital Partners Now Owns 10.2% of Jounce Therapeutics247wallst.com - March 17 at 7:18 PMJounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian Cancerfinance.yahoo.com - March 16 at 7:06 PMJounce (JNCE) Up 41% on Buyout Offer From Concentra Biosciencesfinance.yahoo.com - March 16 at 2:06 PM10% Owner of Jounce Therapeutics Makes $85K Buybenzinga.com - March 15 at 2:17 PMWhy Jounce Therapeutics Stock Is Moving Higher Today?finance.yahoo.com - March 15 at 2:17 PMConcentra Biosciences Proposes To Acquire Jounce Therapeutics - Quick Factsmarkets.businessinsider.com - March 15 at 9:17 AMTang Capital Partners Now Owns 10.20% of Jounce Therapeutics (JNCE)msn.com - March 15 at 9:17 AMJounce Therapeutics Jumps Premarket on Buyout Bid >JNCEmarketwatch.com - March 15 at 9:17 AMWhy Is Jounce Therapeutics (JNCE) Stock Up 37% Today?investorplace.com - March 15 at 8:03 AMJounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra Biosciencesfinance.yahoo.com - March 15 at 12:05 AMJounce Therapeutics stock bounces after saying only 1.4% of its cash was in an SVB operating accountfinance.yahoo.com - March 13 at 10:56 AMJounce Therapeutics Full Year 2022 Earnings: Beats Expectationsfinance.yahoo.com - March 11 at 9:16 AMMoore Kuehn Encourages ROCC, JNCE, BRMK, and FOCS Investors to Contact Law Firmbenzinga.com - March 1 at 6:49 PMJOUNCE THERAPEUTICS INVESTOR ALERT by the Former...benzinga.com - March 1 at 8:48 AMSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Jounce Therapeutics, Inc. Mergerbenzinga.com - February 23 at 5:12 PMCambridge biotech Jounce to cut staff, merge with U.K. drug developerfinance.yahoo.com - February 23 at 5:12 PMJounce Therapeutics, Inc.: Redx and Jounce Announce Recommended Business Combinationfinanznachrichten.de - February 23 at 9:00 AMJounce Shares Bounce Higher on Tie-Up With Redx >JNCEmarketwatch.com - February 23 at 9:00 AMRaymond James downgrades Jounce Therapeutics (JNCE) to a Holdmarkets.businessinsider.com - February 23 at 9:00 AMJounce stock soars ~35% on all-stock merger with Redx Pharmamsn.com - February 23 at 9:00 AMRedx and Jounce Announce Recommended Business Combinationfinance.yahoo.com - February 23 at 4:00 AMJounce Therapeutics Shares Up 12% After Hours On Layoff Plansmarketwatch.com - February 22 at 10:59 PMJounce Therapeutics Announces Restructuringfinance.yahoo.com - February 22 at 5:58 PMShort Interest in Jounce Therapeutics, Inc. (NASDAQ:JNCE) Declines By 46.3%marketbeat.com - January 27 at 6:55 AMCowen Financial Products LLC Ups Stake in Jounce Therapeutics Inc (JNCE)nasdaq.com - January 25 at 2:32 PMJounce Therapeutics, Inc. (NASDAQ:JNCE) Shares Sold by Trv Gp II LLCmarketbeat.com - January 20 at 10:50 AMAssenagon Asset Management S.A. Sells 571,100 Shares of Jounce Therapeutics, Inc. (NASDAQ:JNCE)marketbeat.com - January 13 at 5:27 AMJNCE.O - | Stock Price & Latest News | Reutersreuters.com - January 12 at 2:15 PMGilead's (GILD) Application for Trodelvy Gets EMA Validationfinance.yahoo.com - January 4 at 3:20 PMGilead Sciences Acquires Jounce Therapeutics Cancer Immunotherapy Programfinance.yahoo.com - December 28 at 1:35 PM Get Jounce Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JNCE and its competitors with MarketBeat's FREE daily newsletter. Email Address [Shocking] Elon Musk’s Plan To End Banks (Ad)Leaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. Click here now to get your copy. JNCE Media Mentions By Week JNCE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. JNCE News Sentiment▼0.000.48▲Average Medical News Sentiment JNCE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. JNCE Articles This Week▼00▲JNCE Articles Average Week Get Jounce Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JNCE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SGMO News CRIS News BLUE News DTIL News LIFE News VIGL News ALVR News PLX News OTLK News CVM News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:JNCE) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jounce Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
